[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574604":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":51,"collaborators":25,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":25,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":25,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":25,"overallStatus":38,"whyStopped":25,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Wecare Probiotics Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Probiotic","EXPERIMENTAL","Every day to Pediococcus acidilactici PA53 (30 billion CFU\u002Fday, 3g) intervention, for 8 weeks.\n\nStore in a cool and dry place.",[13],"Dietary Supplement: Probiotic",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Every day to give 3 g maltodextrin intervention for 8 weeks. Store in a cool and dry place.",[19],"Dietary Supplement: Maltodextrin",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DIETARY_SUPPLEMENT","The experimental phase of this study had last 8 weeks and each patient will make 3 visits (week 0, week 4, week 8).",[9],null,{"type":22,"name":27,"description":23,"armGroupLabels":28,"otherNames":25},"Maltodextrin",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Yuhan xia, Doctor","CONTACT","18336086291","1959643812@qq.com",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":25,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Department of Nutrition, General Hospital of Ningxia Medical University","RECRUITING","Yinchuan","Ningxia","China","CN",{"type":44,"coordinates":45},"Point",[46,47],106.27306,38.46806,{"lat":47,"lon":46},[50],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},{"type":52,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100574604","to-evaluate-the-safety-and-efficacy-of-pediococcus-acidilactici-pa53-in-relieving-constipation-in-adults-100574604",false,"NCT06761443","To Evaluate the Safety and Efficacy of Pediococcus Acidilactici PA53 in Relieving Constipation in Adults","Based on a Randomized, Double-blind, Placebo-controlled Trial, we Evaluated the Safety and Efficacy of Pediococcus Acidilactici PA53 in Relieving Constipation in Adults","Inclusion Criteria:\n\n1\\. Constipated subjects Subjects (less than 3 bowel movements per week and\u002For Bristol Scale Types 1 and 2); 2. Be able to complete the research according to the requirements of the test plan; 3. Subjects who have signed informed consent; 4. Subjects (including male subjects) have no family planning and voluntarily take effective contraceptive measures from 14 days before screening to 6 months after the end of the trial.\n\n\\-\n\nExclusion Criteria:\n\n1. Short-term use of items with similar functions to the subject, which affects the judge of the result;\n2. Those who changed their diet type during the study period;\n3. People with severe allergies and immune deficiencies;\n4. Women who are pregnant, breastfeeding or planning to become pregnant;\n5. Patients with serious diseases of cardiovascular, lung, liver, kidney and other vital organs, diabetes, thyroid disease, severe metabolic diseases, malignant tumors, and severe immune system diseases;\n6. People who have used antibiotics in the past two weeks;\n7. People with serious mental and mental illness;\n8. Failure to eat the test sample as required, or failure to follow up on time, resulting in uncertain efficacy;\n9. Other researchers judged it inappropriate to participate. -",true,"ALL","18 Years","70 Years",{"count":65,"type":66},10,"ESTIMATED","INTERVENTIONAL",[69],"NA","To study the improvement of constipation symptoms, quality of life and mental state, intestinal function, intestinal hormones, inflammation and immunity, and intestinal flora of constipation subjects after 8-week intervention with Pediococcus acidilactici PA53.",[72],"Constipation","2025-01-01",{"date":75,"type":76},"2025-01-07","ACTUAL",{"date":78,"type":66},"2025-02-25",{"date":80,"type":66},"2025-05-25",{"name":5,"class":6},1]